Authors

Jason J. Luke, MD, FACP, University of Chicago Medicine

Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center

Jason J. Luke, MD, University of Chicago

Jason Luke, MD

Jason Luke, MD, associate director for clinical research and director of the Immunotherapy and Drug Development Center at Hillman Cancer Center, University of Pittsburgh.

Latest:

SUPRAME Trial Propels the Development of TCR-Based Therapy in Cutaneous Melanoma: With Jason Luke, MD

Dr Luke discusses the rationale for evaluating IMA203 in cutaneous melanoma and what the PRAME trial findings may mean for the future of TCR therapy.

Jason M. Broderick

Latest:

Imlunestrant With/Without Abemaciclib Maintains PFS, OS Benefit in ER+/HER2– Breast Cancer

Imlunestrant alone or in combination with abemaciclib significantly improved PFS in ER-positive and HER2-negative breast cancer.

Jason M. Long, MD

Latest:

Dr. Long on Surgical Advances in NSCLC

Jason M. Long, MD, assistant professor of surgery, Division of Cardiothoracic Surgery, University of North Carolina at Chapel Hill, discusses specific minimally invasive thoracic surgery approaches in lung cancer.

Jason M. Wallen, MD, MBA, FACS, FCCP

Latest:

Dr. Wallen on Surgery in Patients With Advanced Lung Cancer

Jason M. Wallen, MD, MBA, FACS, FCCP, associate professor of surgery, division chief of thoracic surgery, director of gastric and esophageal cancer program, medical director of the thoracic oncology program, Upstate University Hospital, discusses the role of surgery in patients with advanced-stage lung cancer.

Jason Matney, PhD

Latest:

Jason Matney on Deep Inspiration Breath Hold During Radiation Therapy for Breast Cancer

Jason Matney, PhD, clinical assistant professor, Physics and Computing Division, Department of Radiation Oncology, UNC School of Medicine, discusses a prospective assessment of deep inspiration breath hold to prevent radiation-associated cardiac perfusion defects in patients with left-sided breast cancer.

Jason Valent, MD

Latest:

Dr. Valent on Ongoing Research With Immunotherapy in Multiple Myeloma

Jason Valent, MD, an oncologist at Cleveland Clinic, discusses ongoing research with immunotherapy, specifically checkpoint inhibitors, in the treatment of patients with multiple myeloma.

Jason Westin, MD

Latest:

Future Outlooks in the Treatment of R/R DLBCL

Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.

Jason Westin, MD, MS, FACP, MD Anderson Cancer Center

Latest:

Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

Jason Westin, MD, The University of Texas MD Anderson Cancer Center

Latest:

Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.

Jason Y. Cheng, PhD

Latest:

Primary Radiation Therapy for Myeloid Sarcoma of the Porta Hepatis

Treating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.

Jatin J. Shah, MD

Latest:

Dr. Shah on Novel Therapies for Multiple Myeloma

Jatin J. Shah, MD, from the University of Texas, MD Anderson Cancer Center, describes his excitement over novel therapeutics in development for patients with multiple myeloma.

Jatin J. Shah, MD, MD Anderson Cancer Center

Jatin J. Shah, MD, The University of Texas MD Anderson Cancer Center

Jatin P. Shah, MD, MD Anderson Cancer Center

Javier A. Pinilla-Ibarz, MD, PhD

Latest:

Introductions & Framework for CLL Treatment

Explore the evolving treatment landscape for Chronic Lymphocytic Leukemia, focusing on BTK and BCL2 inhibitor strategies and biomarker testing insights.

Javier A. Pinilla-Ibarz, MD, PhD, H. Lee Moffitt Cancer Center

Javier Cortes, MD, PhD

Latest:

Dr Cortés on Analyzing Outcomes With T-DXd in HER2+ Breast Cancer With Brain Metastases

Javier Cortés, MD, PhD, discusses the rationale for analyzing outcomes with trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who have brain metastases.